These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2261913)

  • 1. Long-term management of differentiated thyroid cancer.
    Ross DS
    Endocrinol Metab Clin North Am; 1990 Sep; 19(3):719-39. PubMed ID: 2261913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
    Mazzaferri EL; Kloos RT
    Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differentiated thyroid cancer -- 2009].
    Konrády A
    Orv Hetil; 2011 Jan; 152(5):163-70. PubMed ID: 21247857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
    Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exophytic and ulcerated local recurrence of papillary thyroid carcinoma with spectacular response to external beam radiotherapy.
    Gkountouvas A; Thomas D; Tertipi A; Chrysanthou K; Kaldrimidis P
    Thyroid; 2008 Sep; 18(9):1015-6. PubMed ID: 18788923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts in the management of differentiated thyroid cancer.
    Intenzo CM; Jabbour S; Dam HQ; Capuzzi DM
    Semin Nucl Med; 2005 Oct; 35(4):257-65. PubMed ID: 16150246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors.
    Leboeuf R; Emerick LE; Martorella AJ; Tuttle RM
    Thyroid; 2007 Jun; 17(6):543-7. PubMed ID: 17614775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of thyroid cancer.
    Blahd WH
    Compr Ther; 1993; 19(5):197-202. PubMed ID: 8275665
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thyroglobulin, 131I-whole body scintigraphy and risk factors in the follow-up of differentiated thyroid cancer].
    Berding G; Hüfner M; Georgi P
    Nuklearmedizin; 1992 Feb; 31(1):32-7. PubMed ID: 1561118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary and follicular thyroid carcinoma.
    Schlumberger MJ; Torlantano M
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):601-13. PubMed ID: 11289737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation.
    Rosario PW; Furtado MS; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 May; 22(5):482-6. PubMed ID: 22175271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.